Categories Earnings, Other Industries

Bio-Path likely to report wider Q2 loss on Aug. 15

Bio-Path Holdings (NASDAQ: BPTH) is expected to continue incurring significant operating losses in the second quarter. Also, the losses are likely to increase substantially as the biotech company expand its drug development programs and commercialization efforts. The company is set to release its second-quarter earnings results on Thursday before the bell.

The company had an accumulated deficit of $49.3 million as of March 31, 2019. Achieving profitability remained every company’s dream but for this Bio-Path should develop one or more of its drug candidates or enter into license or development agreements with third parties.

Bio-Path expects to finance its foreseeable cash requirements through cash on hand, cash from operations, debt financings and public or private equity offerings. The company could seek collaborations and license arrangements for its drug candidates. It now has no lines of credit or other arranged access to debt financing.

Image for representation. Courtesy: PublicDomainPictures from Pixabay

The company has not generated significant revenues to date and does not expect revenues from its drug candidates to occur for many years. However, the successful development and eventual commercialization of its drug candidates are likely to be the key behind revenue generation. This could be achieved from a combination of product sales, third-party grants, service agreements, strategic alliances, and licensing arrangements.

The company operates as a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company in the US. Bio-Path’s lead drug candidate is prexigebersen, which is in Phase 2 clinical trials for cancer treatment. It is also developing Liposomal Bcl2 for the treatment of lymphoma, and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer.

Also read: Celsion Q2 earnings preview

For the first quarter, Bio-Path reported a narrower loss helped by a 56% dip in research and development expenses. The company experienced a decline in clinical trial expenses as the operations between stage 1 and stage 2 of phase 2 clinical trial in acute myeloid leukemia (AML) were modified to include venetoclax combination treatment with prexigebersen.

The company anticipates the completion of the Investigational New Drug-enabling studies in 2019 through early 2020, and the filing of an IND application for a phase 1 study of BP1003 for the treatment of pancreatic cancer in 2020.

We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

Most Popular

ADBE Earnings: Adobe reports higher Q2 earnings; results beat estimates

Design software maker Adobe Inc. (NASDAQ: ADBE) on Thursday reported an increase in second-quarter 2024 revenue and earnings. The results also topped expectations. Second-quarter revenues came in at $5.31 billion,

Dollar Tree (DLTR): A look at the discount retailer’s growth initiatives at its namesake banner

Shares of Dollar Tree, Inc. (NASDAQ: DLTR) were down over 1% on Thursday. The stock has dropped 24% year-to-date. The company delivered sales and GAAP earnings growth for the first

Key highlights from Signet Jewelers’ (SIG) Q1 2025 earnings results

Signet Jewelers Limited (NYSE: SIG) reported first quarter 2025 earnings results today. Sales decreased 9.4% year-over-year to $1.5 billion. Sales were down 9.6% on a constant currency basis. Same-store sales

Comments

  1. Pingback: Leandro Farland
  2. Pingback: pH Meters
  3. Pingback: البحث
  4. Pingback: fue
  5. Pingback: fue
  6. Pingback: Young Arab Voices
  7. Pingback: Character building
  8. Pingback: MSc in pharmacy
  9. Pingback: Tahya Misr Fund
  10. Pingback: Fiverr Earn
  11. Pingback: Fiverr Earn
  12. Pingback: Fiverr Earn
  13. Pingback: fiverrearn.com
  14. Pingback: fiverrearn.com
  15. Pingback: fiverrearn.com
  16. Pingback: aussiedoodle
  17. Pingback: future university
  18. Pingback: future university
  19. Pingback: frenchie puppies
  20. Pingback: Fiverr
  21. Pingback: Fiverr
  22. Pingback: Warranty
  23. Pingback: Piano repairs
  24. Pingback: FUE
  25. Pingback: FUE
  26. Pingback: Packing expertise
  27. Pingback: Classic Books 500
  28. Pingback: FiverrEarn
  29. Pingback: FiverrEarn
  30. Pingback: FiverrEarn
  31. Pingback: Speaker
  32. Pingback: partners
  33. Pingback: FiverrEarn
  34. Pingback: live sex cams
  35. Pingback: live sex cams
  36. Pingback: FiverrEarn
  37. Pingback: FiverrEarn
  38. Pingback: FiverrEarn
  39. Pingback: FiverrEarn
  40. Pingback: FiverrEarn
  41. Pingback: FiverrEarn
  42. Pingback: FiverrEarn
  43. Pingback: wix login
  44. Pingback: watch
  45. Pingback: Slot Online
  46. Pingback: Slot Thailand
  47. Pingback: Kuliah Termurah
  48. Pingback: FiverrEarn
  49. Pingback: FiverrEarn
  50. Pingback: FiverrEarn
  51. Pingback: FiverrEarn
  52. Pingback: FiverrEarn
  53. Pingback: FiverrEarn
  54. Pingback: cheap sex cams
  55. Pingback: french bulldog
  56. Pingback: live sex cams
  57. Pingback: live sex cams
  58. Pingback: marketplace
  59. Pingback: frt trigger
  60. Pingback: Litigio fiscal
  61. Pingback: 늑대닷컴
  62. Pingback: Kasino online
  63. Pingback: One Peace AMV
  64. Pingback: nangs near me
  65. Pingback: allgame
  66. Pingback: 918kiss
  67. Pingback: หวย24
  68. Pingback: pg slot
  69. Pingback: AI Lawyer
  70. Pingback: cybersécurité
  71. Pingback: Raahe Guide
  72. Pingback: Raahe Guide
  73. Pingback: 44 mag ammo
  74. Pingback: ozempic
  75. Pingback: SaaS Law Firm
  76. Pingback: Skywhip tanks
  77. Pingback: shanghai jobs

Comments are closed.

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top